Merck & Company, Inc. (MRK) is currently trading at $127.47. Based on 26 Wall Street analysts, the average target price is $134.04, implying a 5.2% upside. The consensus recommendation is BUY.

MRK

Merck & Company, Inc.

HealthcareOpinion: buy

Opinion Criteria: Based on the consensus of Wall Street analysts. Strong Buy (1.0-1.5), Buy (1.5-2.5), Hold (2.5-3.5), Sell (3.5-4.5), Strong Sell (4.5-5.0).

Price (USD)

$127.47

Consensus target price range

Low–high band from analyst PT changes in the last 3 months; median & sample mean vs current price

LowHigh
$113.00$155.00
Current $127.47
Median: $142.00Mean: $139.18Current: $127.47

Recent price target updates (latest 80)

  • JP MorganJul 13, 2026

    PT action: Raises

    $135.00 → $140.00

  • BMO CapitalJul 13, 2026

    PT action: Raises

    $135.00 → $142.00

  • GuggenheimJul 13, 2026

    PT action: Raises

    $140.00 → $145.00

  • Morgan StanleyJul 9, 2026

    PT action: Raises

    $112.00 → $113.00

  • RBC CapitalJul 8, 2026

    PT action: Maintains

    $142.00 → $142.00

  • Wells FargoJul 8, 2026

    PT action: Raises

    $145.00 → $150.00

  • Cantor FitzgeraldJul 6, 2026

    PT action: Maintains

    $120.00 → $120.00

  • B of A SecuritiesJun 30, 2026

    PT action: Raises

    $130.00 → $141.00

  • ScotiabankJun 30, 2026

    PT action: Raises

    $136.00 → $155.00

  • CICCJun 24, 2026

    PT action: Announces

    $0.00 → $138.00

  • Wells FargoMay 1, 2026

    PT action: Lowers

    $150.00 → $145.00

  • UBSApr 13, 2026

    PT action: Raises

    $130.00 → $145.00

  • JP MorganApr 6, 2026

    PT action: Raises

    $125.00 → $135.00

  • RBC CapitalMar 30, 2026

    PT action: Maintains

    $142.00 → $142.00

  • CitigroupMar 20, 2026

    PT action: Raises

    $120.00 → $125.00

  • Wells FargoMar 12, 2026

    PT action: Raises

    $135.00 → $150.00

  • RBC CapitalFeb 25, 2026

    PT action: Announces

    $0.00 → $142.00

  • BarclaysFeb 20, 2026

    PT action: Announces

    $0.00 → $140.00

  • Freedom BrokerFeb 9, 2026

    PT action: Raises

    $90.00 → $110.00

  • GuggenheimFeb 6, 2026

    PT action: Raises

    $122.00 → $140.00

Band uses only the revised target (Current column) from firm actions dated within the last 3 months—not the Prior price.

Avg Target

$134.04

Based on 26 analysts

Analyst Recommendations

Buy (19)Hold (8)Sell (1)

Upside

+5.15%

Market Cap

$0.00B

Financial & Investment Metrics

P/E Ratio (TTM)35.91
Forward P/E13.20
P/B Ratio6.86
Dividend Yield2.69%
Return on Equity (ROE)18.94%
Operating Margin38.60%
Debt to Equity106.94
Beta (Volatility)0.20
52 Week Range$76.66 - $131.74
LowCurrent: $127.47High

Latest News

Daily editorial mentioning MRK

Price target moves

AMD and Materials Sector Adjustments Lead July 1 Consensus Revisions

The most aggressive move in the latest data, current as of 2026-07-01T00:13:14.031Z, comes from Wells Fargo’s valuation of Advanced Micro Devices (AMD), which surged from 505 to 615. This $110 jump stands in sharp contrast to the more tempered adjustments seen across the broader S&P 500. While AMD captured the spotlight, the Materials sector faced a wave of downward pressure, most notably with B of A Securities lowering its outlook for Celanese (CE) from 72 to 63 and LyondellBasell (LYB) from 68 to 48.

The week in PT changes

The recent session was defined by a distinct push-pull dynamic between the Information Technology and Materials sectors. BTIG joined the bullish camp for Palo Alto Networks (PANW), lifting the target to 380 from 333. Meanwhile, the Financials sector saw a series of nuanced updates; Citigroup and Oppenheimer both adjusted their targets for PNC Financial Services (PNC), settling at 280 and 271, respectively.

The Materials sector, however, faced broad skepticism from analysts. Beyond the aforementioned shifts for CE and LYB, B of A Securities also trimmed its stance on Dow Inc. (DOW), dropping the target to 29 from 35. UBS followed suit, cutting Newmont (NEM) from 140 to 120. These reductions reflect a collective reassessment of the sector's near-term earnings potential.

Ticker Firm Dir Prior→Current
AMD Wells Fargo up 505→615
PANW BTIG up 333→380
ZTS TD Cowen down 150→104
LYB B of A Securities down 68→48

What the data does not say

One detail that warrants scrutiny is the wide gap between individual firm revisions and the broader consensus mean. For instance, while TD Cowen slashed its target for Zoetis (ZTS) to 104 from 150, the resulting 72.6% implied upside suggests that the firm's view is now significantly more conservative than the aggregate market sentiment. Analysts are clearly recalibrating models following recent volatility, but these specific price changes do not inherently signal a change in the underlying business fundamentals or macroeconomic environment. A lower target is often just a mathematical adjustment to match current trading patterns, not necessarily a fundamental critique of the company's long-term value. Investors should be wary of assuming these revisions are predictive of immediate price action, as they primarily represent a reflection of shifting institutional models rather than a mandate on future performance.

Read article

Insider Sentiment Index (Last 6 Months)

Counts and listings exclude stock awards, gifts, and option exercises—open-market purchases and sales only.

Buy vs Sell (Count)

Insider Buys: 0Insider Sells: 10

Whale Trades (C-Level Large Buys)

No major insider buying detected recently.

Recent Insider Transactions

DateNamePositionTransactionShares
2/12/2026GUINDO CHIRFIOfficerSale at price 121.46 per share.10,000
2/10/2026LI DEAN YOfficerSale at price 117.52 per share.10,235
2/9/2026GUINDO CHIRFIOfficerSale at price 118.41 per share.10,000
2/9/2026ZACHARY JENNIFER LGeneral CounselSale at price 119.15 per share.121,573
2/6/2026DELUCA RICHARD ROBERT JR.OfficerSale at price 120.92 per share.37,685
2/6/2026OOSTHUIZEN JOHANNES JACOBUSOfficerSale at price 121.87 per share.15,000
2/6/2026WILLIAMS DAVID MICHAELChief Technology OfficerSale at price 121.90 per share.5,000
2/5/2026GUINDO CHIRFIOfficerSale at price 121.88 per share.20,000
2/4/2026DAVIS ROBERT MChief Executive OfficerSale at price 117.38 - 118.35 per share.47,434
2/4/2026LITCHFIELD CAROLINEChief Financial OfficerSale at price 119.61 per share.41,997

Frequently Asked Questions

Q. What is the current target price and upside for MRK?

A. The current target price for Merck & Company, Inc. is $134.04, which implies a 5.2% upside from the current price of $127.47. This is based on the consensus of 26 Wall Street analysts.

Q. What is the current analyst recommendation for MRK?

A. Currently, there are 4 Strong Buy, 15 Buy, 8 Hold, 0 Sell, and 1 Strong Sell ratings. The overall consensus is BUY.

Q. Are insiders buying MRK stock recently?

A. Over the past 6 months, there have been 0 insider buys and 10 insider sells. Insider selling is more prominent recently.

Other Promising Stocks in Healthcare

Data provided by Yahoo Finance. This information is for informational purposes only and does not constitute investment advice. We bear no legal responsibility for any investment decisions made based on this data.

Read full disclaimer